Combined HAIC, Lenvatinib and Pucotenlimab As Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma

This study is testing a combination of three treatments — HAIC (a direct liver infusion of chemotherapy), lenvatinib (a targeted oral drug), and pucotenlimab (an immunotherapy) — to try to shrink inoperable bile duct cancer inside the liver enough that surgery becomes possible. **You may be eligible if...** - You are 18 or older with confirmed cancer of the bile ducts inside the liver (intrahepatic cholangiocarcinoma) - Your cancer cannot be surgically removed based on specialist assessment - You have not received any prior systemic treatment for this cancer - Your general health (ECOG 0–1) and liver and kidney function meet study requirements - You have at least one measurable tumor **You may NOT be eligible if...** - You have previously received chemotherapy or immunotherapy for this cancer - You have active autoimmune disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.